A physician-level review of the cancer risk signals associated with NMN and NR supplementation, covering NAD+ biology, preclinical tumor-promotion data, clinical trial safety reports, and practical guidance for patients and prescribers.
NMN trials show no BP increase; one study found systolic BP dropped ~6 mmHg at 250mg/day over 12 weeks. Long-term cardiac data still limited.
A clinician-level comparison of compounded and branded nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR): bioavailability, purity, regulatory status, cost, and how to choose based on current trial data.
A breakdown of NMN and NR (nicotinamide mononucleotide and nicotinamide riboside) as NAD+ precursors for muscle preservation, covering clinical trial data, dosing protocols, and who benefits most.
A evidence summary on CJC-1295 (modified GRF) used off-label for longevity. Covers mechanism, clinical trial data, safety, GRADE evidence level, and what the FDA has approved.
Enclomiphene citrate is used off-label to raise LH, FSH, and testosterone in men with secondary hypogonadism while preserving sperm production. This article reviews the trial evidence, compares it to clomiphene, and outlines a monitoring framework for clinician discussion.
A guide to off-label finasteride use in gender-affirming care, covering mechanism, dosing protocols, evidence quality, safety monitoring, and FDA-approved context.
A guide to ipamorelin acetate for fat loss, covering off-label status, available clinical evidence, dosing protocols, and monitoring requirements.
Metformin is used off-label for PCOS to improve insulin sensitivity, restore ovulation, and lower androgen levels. Learn what the clinical trials show, who benefits most, and what risks to weigh before starting.
Metformin is FDA-approved for type 2 diabetes, but clinicians increasingly prescribe it off-label for weight maintenance. This evidence-based guide covers the clinical trial data, GRADE evidence levels, risks, and who may benefit most.
Ozempic isn't FDA-approved for kidney protection, but the FLOW trial found a 24% drop in kidney failure risk. See dosing, UACR effects, and monitoring needs.
A clinical review of sermorelin acetate used off-label for adult GHD, covering the evidence base, FDA status, dosing, safety, and how it compares to approved GH therapy.
A guide to using sermorelin acetate off-label for post-injury, post-surgical, and exercise recovery. Covers mechanism, evidence level, dosing protocols, and required monitoring.
A guide to using sermorelin acetate off-label for sleep improvement: what the research shows, GRADE-level evidence, dosing considerations, safety risks, and how to weigh the tradeoffs.
Can Wegovy (semaglutide 2.4 mg) treat alcohol use disorder? Review the clinical trial evidence, off-label prescribing rationale, GRADE quality rating, and monitoring requirements for patients and clinicians.
Semaglutide 2.4 mg (Wegovy) is being studied off-label for alcohol use disorder. This guide covers the trial data, mechanistic rationale, GRADE-level evidence, real risks, and how to talk to your prescriber.
A detailed clinical review of tirzepatide (Zepbound) for polycystic ovary syndrome: off-label status, trial data, mechanism, dosing, risks, and guideline context.
A guide to how oral micronized progesterone (Prometrium) affects hair growth, hair loss, sebum, and skin quality, with primary-literature citations and dosing context.
Does low-dose oral minoxidil affect appetite or cravings? A clinician-level review of the evidence, proposed mechanisms, dosing context, and what patients should monitor.
A analysis of whether low-dose oral minoxidil affects bone mineral density, what the current evidence shows, and how to monitor patients on long-term therapy.
A analysis of the cancer risk signal associated with oral minoxidil use for hair loss, covering pharmacology, animal data, human epidemiology, FDA labeling, and clinical guidance for prescribers.
A comparison of compounded and branded oral minoxidil for hair loss, covering formulation differences, dosing evidence, safety, cost, and how to choose the right option.
Oral minoxidil mainly causes hypertrichosis, not hyperpigmentation, in 14 to 38% of users. See dosing, timeline, and reversibility details.
Why oral minoxidil stops working, how to identify a true plateau versus expected shedding, and the clinical steps to restore hair growth. MD-level guidance with primary literature citations.
A clinical deep-dive into low-dose oral minoxidil for hair loss after bariatric surgery, covering pharmacokinetics, dosing, cardiovascular monitoring, and drug interactions specific to post-bariatric patients.
A clinician-level guide to safely restarting low-dose oral minoxidil after acute illness, including dose titration, cardiovascular monitoring, and hair-shedding expectations backed by primary literature.
A clinician-level review of how low-dose oral minoxidil affects sleep architecture, including cardiovascular mechanisms, fluid retention, heart rate changes, and practical dosing strategies to minimize nighttime disruption.
How to dose Ozempic (semaglutide 0.5 to 2.0 mg) in patients aged 65 and older. Covers starting dose, titration schedule, renal adjustment, fall risk, drug interactions, and deprescribing, with full trial evidence and guideline citations.
No washout is needed. Time your first Ozempic dose to your next Trulicity injection, start at 0.25 mg, and retitrate over 8 to 16 weeks.
A clinical deep-dive into how Ozempic (semaglutide 0.5 to 2.0 mg) reduces appetite and changes food cravings, with primary-literature citations, dose-by-dose data, and practical guidance for patients and prescribers.
A comprehensive clinical guide to semaglutide 0.5 to 2.0 mg (Ozempic) use in patients with autoimmune disease, covering immune modulation, disease-specific risks, dosing considerations, and monitoring protocols.
A clinician-level review of how semaglutide 0.5 to 2.0 mg affects liver enzymes, hepatic fat, MASLD/MASH, and safety monitoring in type 2 diabetes and weight management.
Why weight loss stalls on Ozempic (semaglutide 0.5 to 2.0 mg), what the clinical evidence says about dose optimization, and the step-by-step protocol HealthRX.com clinicians use to break a plateau or identify true non-response.
A guide to using Ozempic (semaglutide 0.5 to 2.0 mg) after bariatric surgery, covering indications, dosing, pharmacokinetics, safety, and what the evidence actually shows.
Evidence-based guidance on how to safely restart semaglutide (Ozempic 0.5 to 2.0 mg) after an acute illness interruption, including dose titration, timing, monitoring, and red flags.
A guide to the Ozempic pre-surgery hold window, covering ASA and ESAIC guidelines, aspiration risk, GI motility data, and a practical dosing timeline for patients on semaglutide 0.5 to 2.0 mg.
A guide to the federal and Alabama-specific legal framework for AOD-9604, including FDA status, compounding pharmacy rules, and how to get a legitimate prescription.
A detailed breakdown of AOD-9604's legal status in Alabama, covering FDA scheduling, the 503A/503B compounding framework, the Alabama Board of Pharmacy rules, and what patients need to do to obtain it legally.
A breakdown of AOD-9604's legal status in Arizona, covering FDA bulk-drug regulations, 503A/503B compounding pharmacy rules, the Arizona State Board of Pharmacy, and what a legitimate prescription pathway looks like.
A guide to AOD-9604's legal status in Colorado, covering FDA scheduling, 503A/503B compounding rules, the Colorado State Board of Pharmacy, and how patients can access the peptide through a licensed telehealth or clinic provider.
A guide to AOD-9604's federal and Florida legal status, covering FDA bulk-drug rules, 503A/503B compounding pharmacy pathways, and how to get a legitimate prescription.
A guide to AOD-9604's legal status in Florida, covering FDA bulk sterile compounding restrictions, 503A/503B pharmacy rules, the Florida Board of Pharmacy, and what a legitimate prescription pathway looks like in 2025.
A guide to AOD-9604's legal status in Georgia, covering FDA regulatory classification, 503A/503B compounding pharmacy rules, Georgia state pharmacy board requirements, and how patients can access AOD-9604 through a licensed provider.
A guide to the legal status of AOD-9604 in Georgia, covering FDA bulk-drug lists, 503A/503B compounding rules, the Georgia State Board of Pharmacy, and what patients need to know before seeking a prescription.
AOD-9604 is not FDA-approved and sits in a federal regulatory gray area. Illinois residents can access it only through licensed compounding pharmacies under a valid prescription. Learn the exact legal pathway, the 503A/503B framework, and what a telehealth visit should cover.
A breakdown of AOD-9604's legal status in Illinois, covering FDA bulk drug regulations, 503A/503B compounding, Illinois pharmacy board rules, and what patients need to know before seeking a prescription.
A guide to the federal and Maryland-specific legal status of AOD-9604, covering FDA classification, 503A/503B compounding rules, and how Maryland residents can access this peptide through legitimate medical channels.
A detailed look at AOD-9604's federal regulatory status, Michigan state pharmacy law, and what patients and prescribers need to know before pursuing this peptide in 2025.
A breakdown of AOD-9604's federal and Missouri-specific legal status, including FDA classification, compounding pharmacy rules, and how patients can access it legally.
A guide to the federal and North Carolina regulatory status of AOD-9604, including FDA bulk-drug rules, 503A/503B compounding pharmacy requirements, and how to obtain it through a licensed provider.
A guide to AOD-9604's legal status in Oregon, covering FDA scheduling, 503A/503B compounding rules, the Oregon Board of Pharmacy, and what patients and providers need to know in 2025.
A breakdown of AOD-9604's federal and Pennsylvania regulatory status, covering FDA bulk drug lists, 503A/503B compounding, and how a licensed prescriber and compounding pharmacy pathway works. Educational information for editorial and clinical review, not individualized medical or legal advice.
A breakdown of AOD-9604's federal and Tennessee-specific legal status, how the FDA bulk substances list affects compounding pharmacies, and what patients need to know before pursuing a prescription.
AOD-9604's legal status in Texas explained: FDA bulk drug list, 503A/503B compounding rules, Texas State Board of Pharmacy regulations, and how to get a legitimate prescription.
A guide to the federal and Washington State legal framework governing AOD-9604, including FDA status, 503A/503B compounding rules, and how to get a legitimate prescription.
AOD-9604 legal status in Washington State explained: FDA bulk-drug lists, 503A/503B compounding rules, state pharmacy board rules, and how to get a legitimate prescription.
A guide to BPC-157's federal and Arizona-specific legal status, covering FDA rules, 503A/503B compounding, and how patients can access it lawfully in 2025.
BPC-157 is not FDA-approved and sits in a regulatory gray zone in California. Learn the federal 503A/503B compounding rules, the California pharmacy board's position, and what patients need to know before seeking a prescription.
A breakdown of BPC-157's legal status in Colorado, covering FDA scheduling, 503A/503B compounding rules, the Colorado pharmacy board, and what patients can actually do in 2025.
A breakdown of BPC-157's federal regulatory status, Illinois-specific access paths, compounding pharmacy rules, and what any Illinois resident needs to know before purchasing or using this peptide.